GSA Capital Partners’s VistaGen Therapeutics VTGN Stock Holding History

GSA Capital Partners’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12K	Buy	54,584 +4,742	+10%	+$2.86K	﹤0.01%	1688
2026 Q1	$28K	Buy	+49,842	New	+$30.3K	﹤0.01%	1633
2025 Q4	–	Sell	-31,486	Closed	-$112K	–	2126
2025 Q3	$112K	Buy	+31,486	New	+$94.1K	0.01%	1511
2023 Q4	–	Sell	-46,782	Closed	-$245K	–	1976
2023 Q3	$245K	Sell	46,782 -152,034	-76%	-$675K	0.02%	1193
2023 Q2	$372K	Buy	198,816 +156,309	+368%	+$548K	0.04%	921
2023 Q1	$159K	Sell	42,507 -127,338	-75%	-$668K	0.02%	1298
2022 Q4	$525K	Sell	169,845 -4,231	-2%	-$15.9K	0.07%	570
2022 Q3	$794K	Buy	174,076 +169,478	+3,686%	+$1.68M	0.11%	265
2022 Q2	$121K	Buy	4,598 +2,132	+86%	+$75.3K	0.02%	1190
2022 Q1	$92K	Buy	+2,466	New	+$108K	0.01%	1303
2021 Q4	–	Sell	-1,066	Closed	-$88K	–	1835
2021 Q3	$88K	Buy	+1,066	New	+$92.6K	0.01%	1333

Other funds holding VTGN

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWS

Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

GSA Capital Partners's VTGN Position: Q2 2026 in Review

GSA Capital Partners increased its VistaGen Therapeutics (VTGN) stake by 9.5% in Q2 2026, buying an estimated $2.86K and bringing the position to 54,584 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1688.

GSA Capital Partners first reported a position in VTGN in Q3 2021 and has held it in 11 quarters since. The position peaked at $794K in Q3 2022. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

GSA Capital Partners held 54,584 shares of VistaGen Therapeutics worth $12K as of Q2 2026.
GSA Capital Partners bought 4,742 VistaGen Therapeutics shares in Q2 2026, an estimated $2.86K.
VistaGen Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1688 holding.
GSA Capital Partners first reported a position in VistaGen Therapeutics in Q3 2021 and has held it in 11 quarters since.
GSA Capital Partners's VistaGen Therapeutics position peaked at $794K in Q3 2022.
25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.